the aid library

LIST OPTIONS

Filter

5058

Download (411)

View PDF (953)

Zambia's national AIDS spending assessment 2010-2012

National HIVAIDS UNAIDS (2014) C1

Download (355)

View PDF (561)

Living Conditions among People with Activity Limitations in Zambia: A National Representative Study.

Arne H Eide & ME Loeb SINTEF Health Research (2006) C1

This research report provides results from the study on living conditions among people with disabilities in Zambia. Comparisons are made between individuals with and without disabilities and also between households with and without a disabled family member. Results obtained in Zambia are also compar... more

Download (614)

View PDF (704)

A case study of the Essential Health Benefit in Tanzania mainland

Todd G.; Nswilla A.; Kisanga O.; Mamdani M. Regional Network for Equity in Health in east and southern Africa (EQUINET) (2017) C1

Regional Network for Equity in Health in east and southern Africa (EQUINET): Disussion Paper 109
This report describes the evolution of mainland Tanzania’s EHB; the motivations for developing the EHBs, the methods used to develop, define and cost them; how it is being disseminated, communicat... more

Download (85)

View PDF (72)

South Africa - Country Cooperation Strategy 2023 - 2027

World Health Organization WHO (2025) C_WHO

The South African WHO Country Cooperation Strategy (CCS) 2023–2027 focuses on four key strategic priorities based on the country’s health needs and disease epidemiology, while also considering the need for building resilient health systems for UHC and health security in the post pandemic period.... more

Download (276)

View PDF (263)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (3110)

View PDF (950)

Sierra Leone: National Community Health Worker Policy 2016–2020

Ministry of Health and Sanitation of Sierra Leone (2016) C1

Download (394)

View PDF (156)

National Guidelines for Integrated Diseases Surveillance and Response Uganda

World Health Organization WHO, Regional Office of Africa; Ministry of Health Uganda (2021) C_WHO

3rd edition. In 2001, Uganda adapted the Integrated Disease Surveillance and Response (IDSR) developed by World Health Organization (WHO) for member states in African region. The Ministry of Health has been implementing the IDSR strategy since then with success across the country. This strategy prov... more

Download (506)

View PDF (1116)

The Wise List 2015

Stockholm Drug and Therapeutics Committee (2015) C_WHO

with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden

Download (204)

View PDF (241)

EMTCT Plus - Framework for Elimination of Mother-to-Child Transmission of HIV, Syphilis, Hepatitis B, and Chagas

F. Pérez; M. B. Mello; L. Sereno; et al. Pan American Health Organization; World Health Organization (2017) C_WHO

The objective of the EMTCT Plus initiative is to achieve and sustain the elimination of mother-to-child transmission of HIV, syphilis, Chagas, and perinatal hepatitis B (HBV) as a public health threat. It embraces the principles and lines of action of the Strategy for Universal Access to Health a... more

Download (346)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (266)

View PDF (270)

Manual for male circumcision under local anaesthesia and HIV prevention services for adolescent boys and men
recommended

World Health Organization WHO (2018) C_WHO

External Link

Communicable disease surveillance and response systems

World Health Organization (2006)

Guide to monitoring and evaluating

Download (18278)

View PDF (2778)

Paediatrics for Doctors in Papua New Guinea

Frank Shann and John Vince (2003)

A guide for doctors providing health services for children. 2nd edition

Download (1276)

View PDF (3150)

Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India + Annexures

Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare (2012) C1

Download (1360)

View PDF (3617)

Birth defects surveillance: Atlas of selected congenital anomalies

World Health Organization (WHO), National Center on Birth Defects and Developmental Disabilities from the United States Centers for Disease Control and Prevention (CDC), International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) (2014) C_WHO

It provides selected illustrations and photographs of congenital anomalies that are severe enough to have a high probability of being captured during the first few days following birth